BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors

BACKGROUND: The prognosis for patients with recurrent glioblastoma is still poor with a median survival between 3 and 6 months. Reports about the application of carmustine (BCNU), one of the standard chemotherapeutic drugs in the treatment of newly diagnosed glioblastoma, in the recurrent situation...

Descripción completa

Detalles Bibliográficos
Autores principales: Reithmeier, Thomas, Graf, Erika, Piroth, Tobias, Trippel, Michael, Pinsker, Marcus O, Nikkhah, Guido
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837009/
https://www.ncbi.nlm.nih.gov/pubmed/20122270
http://dx.doi.org/10.1186/1471-2407-10-30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837009/
https://www.ncbi.nlm.nih.gov/pubmed/20122270
http://dx.doi.org/10.1186/1471-2407-10-30

Ejemplares similares